Work

Generic Immunosuppressants in Hematopoietic Cell Transplantation

Year: 2010

Type: article

Abstract: Successful immune suppression and modulation is a cornerstone in the hematopoietic cell transplantation (HCT) process. Only a limited number of active immunosuppressive compounds are commonly used in HCT. Despite the relatively limited number of HCTs performed in the United States each year, there is a multimillion dollar market for pharmaceutical immunosuppressants, given the more extensive use of these drugs in solid organ transplantation. As such, an active generic immunosuppressant industry has evolved over the past few years.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2010.11.006

Authors: Corey Cutler, Aaron Kesselheim, Steven Gabardi, Borje S. Andersson, Paul Carpenter, Hanna J. Khoury, Mark Litzow, Scott D. Rowley, Scott Lanum, Helen Leather, Ya-Chen Tina Shih, Robert Peter Gale, John R. Wingard, Frederick R. Appelbaum, Claudio Anasetti

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Brigham and Women's Hospital, The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Winship Cancer Institute, Mayo Clinic, Hackensack University Medical Center, Celgene (United States), University of Florida Health, University of Florida, Moffitt Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

Funders: Pfizer, Otsuka America, Johnson and Johnson

OpenAlex ID: W2103305835

FWCI: 1.402

Cites: 22

Cited by: 15

Related to: 10